UltiPace™ Pacing Lead

Stylet-Driven Leads for Left Bundle Branch Area Pacing

Important Safety Information

Proven Design Evolved.

Introducing the UltiPace Pacing Lead, newly engineered from Abbott, the first and only provider of stylet-driven leads that are FDA approved for left bundle branch area pacing (LBBAP).

UltiPace cross section

UltiPace Pacing Leads carry forward the proven distal design of Tendril STS while the proximal lead end has been enhanced with additional layers of insulation to provide increased abrasion and crush resistance.1

vs. Tendril STS1


Increase in abrasion resistance



Increase in lead crush resistance

vs. Tendril MRI 1


Increase in abrasion resistance



Increase in lead crush resistance

Demonstrated LBBAP Success and Safety


93% circle

of patients not experiencing
LBBAP-related adverse effects at  6 months post-implant.2

99.5% circle

Resistant to Distal Fatigue Failure

UltiPace Pacing Leads have a robust distal lead tip without a flexible zone that helps reduce stress on the conductors and the chance for distal fatigue failure compared to competitive leads.3

Ulipace pacing leads

Zero Helix Retraction

The Helix Locking Tool is a proven solution to lock an extended helix during tissue burrowing without retraction.3

healix locking tool

Improved Torque Transmission with Fewer Rotations


Improvement in torsional stiffness when using UltiPace Pacing Leads compared to LBBAP-approved lumenless pacing leads.3

94% circle

Continuous Unipolar Pacing and Impedance Monitoring

Provides the user with uninterrupted feedback to help achieve optimal results.4

Stay Informed

Sign up to hear about our technology, education opportunities, and more.

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.


*Composite success rate of acceptable capture thresholds and sense amplitudes for LBBAP at 6 months post-implant.

  1. Abbott. Data on File. Item: 91010074 Ver A.
  2. Abbott. Left Bundle Branch Area Pacing Study. Item: ARTEN600334504 A.
  3. Abbott. Data on File, Engineering Technical Report. Item: 90994484 Ver D.
  4. Burri, H., Jastrzebski, M., Cano, O., Curila, K., Pooter, J. de, Huang, W., Israel, C., Joza, J., Romero, J., Vernooy, K., Vijayaraman, P., Whinnett, Z., & Zanon, F. (2023). EHRA clinical consensus statement on conduction system pacing implantation: Executive summary. endorsed by the Asia-Pacific Heart Rhythm Society (APHRS), Canadian heart rhythm society (CHRS) and Latin-American heart rhythm society (LAHRS). Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. https:// pubmed.ncbi.nlm.nih.gov/37061850/


UltiPace™ leads are indicated for use in combination with a compatible pacemakers, implantable cardioverter defibrillator (ICDs) or cardiac resynchronization therapy (CRT-P/CRT-D) to provide sensing and pacing for the management of chronic symptomatic bradycardia and various atrioventricular conduction abnormalities in patients who experience syncope, presyncope, fatigue, disorientation due to arrhythmia/ bradycardia, or any combination of these symptoms. The UltiPace leads are implanted transvenously in either the right atrium, the right ventricle or the left bundle branch area.

MAT-2403244 v3.0